CoChat

KRAS-G12C Mutation Is Associated with Poor Outcome in Surgically Resected Lung Adenocarcinoma

Nadal, Ernest, Chen, Guoan, Prensner, John R., Shiratsuchi, Hiroe, Sam, Christine, Zhao, Lili, Kalemkerian, Gregory P., Brenner, Dean, Lin, Jules, Reddy, Rishindra M., Chang, Andrew C., Capellà, Gabriel, Cardenal, Felipe, Beer, David G., Ramnath, Nithya · 2014 · Journal of Thoracic Oncology
Cited by 113

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/jto.0000000000000305

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Research works printed but not linked: 32

  1. Bos, 1989, ras oncogenes in human cancer: a review, Cancer Res, 49, 4682
  2. Capella, 1991, Frequency and spectrum of mutations at codons 12 and 13 of the c-K-ras gene in human tumors, Environ Health Perspect, 93, 125, 10.1289/ehp.9193125 · DOI · Paper page
  3. Maus, 2014, KRAS mutations in non-small-cell lung cancer and colorectal cancer: implications for EGFR-targeted therapies, Lung Cancer, 83, 163, 10.1016/j.lungcan.2013.11.010 · DOI
  4. Westra, 1996, K-ras oncogene activation in atypical alveolar hyperplasias of the human lung, Cancer Res, 56, 2224
  5. Li, 1994, c-k-ras and p53 mutations occur very early in adenocarcinoma of the lung, Am J Pathol, 144, 303
  6. Downward, 2003, Targeting RAS signalling pathways in cancer therapy, Nat Rev Cancer, 3, 11, 10.1038/nrc969 · DOI · Paper page
  7. Bamford, 2004, The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website, Br J Cancer, 91, 355, 10.1038/sj.bjc.6601894 · DOI · Paper page
  8. Garassino, 2011, Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer, Ann Oncol, 22, 235, 10.1093/annonc/mdq680 · DOI · Paper page
  9. Balbin, 2013, Reconstructing targetable pathways in lung cancer by integrating diverse omics data, Nat Commun, 4, 2617, 10.1038/ncomms3617 · DOI · Paper page
  10. Mascaux, 2005, The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis, Br J Cancer, 92, 131, 10.1038/sj.bjc.6602258 · DOI · Paper page
  11. Shepherd, 2013, Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy, J Clin Oncol, 31, 2173, 10.1200/JCO.2012.48.1390 · DOI · Paper page
  12. Goldstraw, 2006, International Staging Project. . The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer, J Thorac Oncol, 1, 281, 10.1016/S1556-0864(15)31581-1 · DOI · Paper page
  13. Chitale, 2009, An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors, Oncogene, 28, 2773, 10.1038/onc.2009.135 · DOI · Paper page
  14. Bolstad, 2003, A comparison of normalization methods for high density oligonucleotide array data based on variance and bias, Bioinformatics, 19, 185, 10.1093/bioinformatics/19.2.185 · DOI · Paper page
  15. Bryant, 2010, Clinically relevant characterization of lung adenocarcinoma subtypes based on cellular pathways: an international validation study, PLoS One, 5, e11712, 10.1371/journal.pone.0011712 · DOI
  16. Gröger, 2012, Meta-analysis of gene expression signatures defining the epithelial to mesenchymal transition during cancer progression, PLoS One, 7, e51136, 10.1371/journal.pone.0051136 · DOI · Paper page
  17. de Hoon, 2004, Open source clustering software, Bioinformatics, 20, 1453, 10.1093/bioinformatics/bth078 · DOI · Paper page
  18. Eisen, 1998, Cluster analysis and display of genome-wide expression patterns, Proc Natl Acad Sci U S A, 95, 14863, 10.1073/pnas.95.25.14863 · DOI · Paper page
  19. Singh, 2012, TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers, Cell, 148, 639, 10.1016/j.cell.2011.12.033 · DOI · Paper page
  20. Feng, 2002, Preferential DNA damage and poor repair determine ras gene mutational hotspot in human cancer, Journal Natl Cancer Inst, 94, 1527, 10.1093/jnci/94.20.1527 · DOI · Paper page
  21. Villaruz, 2013, The prognostic and predictive value of KRAS oncogene substitutions in lung adenocarcinoma, Cancer, 119, 2268, 10.1002/cncr.28039 · DOI · Paper page
  22. Rodenhuis, 1987, Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung, N Engl J Med, 317, 929, 10.1056/NEJM198710083171504 · DOI · Paper page
  23. Slebos, 1990, K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung, N Engl J Med, 323, 561, 10.1056/NEJM199008303230902 · DOI · Paper page
  24. Andreyev, 2001, Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study, Br J Cancer, 85, 692, 10.1054/bjoc.2001.1964 · DOI · Paper page
  25. Angulo, 2008, Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours and identify selective PIK3CA overexpression by gene amplification, J Pathol, 214, 347, 10.1002/path.2267 · DOI
  26. Okayama, 2012, Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas, Cancer Res, 72, 100, 10.1158/0008-5472.CAN-11-1403 · DOI · Paper page
  27. Planck, 2013, Genomic and transcriptional alterations in lung adenocarcinoma in relation to EGFR and KRAS mutation status, PLoS One, 8, e78614, 10.1371/journal.pone.0078614 · DOI
  28. Fiala, 2013, The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer, Cancer Genet, 206, 26, 10.1016/j.cancergen.2012.12.003 · DOI · Paper page
  29. Brugger, 2011, Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer, J Clin Oncol, 29, 4113, 10.1200/JCO.2010.31.8162 · DOI · Paper page
  30. Roberts, 2013, KRAS mutation: should we test for it, and does it matter?, J Clin Oncol, 31, 1112, 10.1200/JCO.2012.43.0454 · DOI · Paper page
  31. Sunaga, 2011, Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy, Mol Cancer Ther, 10, 336, 10.1158/1535-7163.MCT-10-0750 · DOI · Paper page
  32. Barbie, 2009, Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1, Nature, 462, 108, 10.1038/nature08460 · DOI · Paper page

Cited by

See all 113

Metadata

Authors
Nadal, E., Chen, G., Prensner, J. R., Shiratsuchi, H., Sam, C., Zhao, L., Kalemkerian, G. P., Brenner, D., Lin, J., Reddy, R. M., Chang, A. C., Capellà, G., Cardenal, F., Beer, D. G., & Ramnath, N.
Venue
Journal of Thoracic Oncology
Publisher
Elsevier BV
Published
2014-10
Volume
9
Issue
10
Pages
1513-1522
ISSN
1556-0864
Cited by
113
References
15
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: KRAS-G12C Mutation Is Associated with Poor Outcome in Surgically Resected Lung Adenocarcinoma. https://app.cochat.ai/papers/10.1097/jto.0000000000000305
The paper
Nadal, E., Chen, G., Prensner, J. R., Shiratsuchi, H., Sam, C., Zhao, L., Kalemkerian, G. P., Brenner, D., Lin, J., Reddy, R. M., Chang, A. C., Capellà, G., Cardenal, F., Beer, D. G., & Ramnath, N. (2014). KRAS-G12C Mutation Is Associated with Poor Outcome in Surgically Resected Lung Adenocarcinoma. Journal of Thoracic Oncology. https://doi.org/10.1097/jto.0000000000000305

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.